[ENDO2013]干甲状腺片可替代L-T4治疗甲状腺功能减退
发布时间:2013-06-27 | 来源:医脉通
关键词:
干甲状腺片
L-T4
甲状腺功能减退症
ENDO2013
【导语】第95届美国内分泌学会年会(ENDO2013)于2013年6月15-18日在美国旧金山隆重举行。大会旨在为内分泌领域研究人员提供最前沿的科学知识与技术,包括基础和临床研究。本次大会参会人数达9300位,创ENDO年会历史新高,共收到摘要约2600份,ENDO2013希望与会者能从中获得有价值的教育内容和发现新的有启发性的想法以促进临床实践。医脉通精选部分会议亮点研究以飨读者!
在ENDO2013年会上,来自美国沃尔特里德国家军事医学中心的内分泌学专家Thanh D. Hoang报告,干甲状腺片(DTE , Desiccated thyroid extract)有望成为甲状腺功能减退患者标准治疗——左甲状腺素(L-T4)的替代药物。
在壁报讨论会上,Hoang表示,对于TSH水平正常但有甲状腺功能减退症状、且仅服用L-T4治疗的患者,干甲状腺片或许是一个可行的治疗选择。他强调,与L-T4相比,干甲状腺片还有较好的减肥效果。
Hoang说,“目前治疗甲状腺功能减退的金标准是合成的左旋甲状腺素,因此我们想要做这项随机、双盲、交叉研究,来看看两种药物的疗效。”
他和他的同事选择了70名18至65岁的服用6个月左旋甲状腺素的原发性甲状腺功能不足的患者。患者被随机分成两组,一组服用干甲状腺片(DTE),一组服用左旋甲状腺素(L-T4),各服用药物16周。
根据本研究的数据,与服用左旋甲状腺素的患者相比,服用干甲状腺片的患者体重平均减轻1.36kg(78.43kg vs 79.70kg,P<0.001)。
两组患者在神经认知指标方面没有差别,但在研究的最后,研究人员会询问患者更愿意采用哪种治疗方式。
在16周研究的最后,有34名(48.6%)的患者愿意采用干甲状腺片,13名(18.6%)患者倾向于选择左旋甲状腺素,而23名(32.9%)患者两者均可。进一步的分析证实了在4个月的治疗期间,选择DTE的患者获得了更好的减肥效果。
Hoang说,“我们现在知道,对于不满意左旋甲状腺素治疗的甲状腺功能减退患者来说,每天给予一次的干甲状腺片是一个安全、可供尝试的治疗方式,同时,干甲状腺片还能产生适度的减肥效果。”
【研究摘要】
Desiccated thyroid extract compared to levothyroxine in the treatment of hypothyroidism
Thanh Duc Hoang*1, Cara H Olsen2, Vinh Quang Mai3, Patrick W Clyde4 and K M Shakir5
1Walter Reed National Military Me, Silver Spring, MD, 2Uniformed Services University of Health Sciences, Bethesda, MD, 3Walter Reed National Military Me, Bethesda, MD, 4Walter Reed Bethesda National Mi, Silver Spring, MD, 5Walter Reed National Military Medical Center, Bethesda, MD
Context: Patients previously treated with desiccated thyroid extract (DTE), when being switched to levothyroxine (L-T4), occasionally did not feel as well despite adequate dosing based on serum TSH levels.
Objective: To investigate the effectiveness of DTE compared to L-T4 in hypothyroid patients.
Design: Randomized, double-blind, crossover study.
Setting: Walter Reed National Military Medical Center.
Patients: Patients (age 18-65 years) enrolled in the military medical system with primary hypothyroidism on a stable dose of L-T4 for 6 months. 78 patients were enrolled, 70 completed the study.
Intervention: Each patient was randomized to either DTE or L-T4 for 16-weeks and then crossed-over for another 16-week period.
Outcome Measures: Biochemical and neurocognitive tests at baseline and at the end of each treatment period.
Results: With the DTE treatment, patients lost 3 pounds compared to L-T4 treatment (172.9 ± 36.4 lbs vs. 175.7 ± 37.7 lbs, P < 0.001). There were no differences in symptoms and neurocognitive measurements between the two therapies. At the end of the study, 34 patients (48.6 %) preferred DTE; 13 (18.6%) preferred L-T4; and 23 (32.9%) had no preference. In the subgroup analyses, those patients who preferred DTE lost 4 pounds during the DTE treatment compared to L-T4 treatment, and their symptom and auditory memory were significantly better. Five variables (thyroid symptom questionnaire, visual working memory index, serum T3 resin uptake, free T4 and SHBG) were predictors of preference for DTE.
Conclusion: DTE caused modest weight loss and almost half (48.6%) of the study patients expressed preference for DTE over LT4. DTE therapy may be relevant for some hypothyroid patients who remain symptomatic while being biochemically euthyroid on L-T4 therapy.